AOD 9604
Stocked in 5mg, 10mg at MontanaPep in Great Falls, Montana. Sold for laboratory research use only.
| Size | Catalog no. | Price per vial |
|---|---|---|
| 5mg | 5AD | $30 |
| 10mg | AOD10 | $50 |
Classification
Synthetic 16-residue hGH C-terminal fragment; failed its pivotal human obesity trial
Structure and chemistry
AOD-9604 is the hexadecapeptide Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, comprising the C-terminal sequence of human growth hormone (residues 177-191) with an added N-terminal tyrosine, and stabilized by a disulfide bridge between its two cysteine residues. It is variously written as hGH fragment 176-191 or 177-191 depending on numbering convention; both refer to the same 16-residue molecule.
What the published research shows
The preclinical record is genuinely substantive and the human record is genuinely negative — both facts matter. Rodent studies from the Monash University group consistently showed reduced body-weight gain, increased fat oxidation and increased lipolysis. Six human clinical trials enrolled roughly 900 adults. An earlier 12-week trial showed a modest significant effect, but the pivotal 24-week Phase IIb trial in 536 subjects failed to show significant weight loss versus placebo, and development was terminated in 2007.
Mechanism of action
AOD-9604 reproduces the lipolytic and antilipogenic activity of the C-terminal region of hGH without binding the classical growth hormone receptor, and without raising IGF-1 or impairing glucose tolerance. Mouse work has implicated the beta-3 adrenergic receptor pathway, including studies in beta-3-AR knockout animals. The precise mechanism remains incompletely characterized, and whether the rodent pathway operates equivalently in humans was never resolved.
Development history
Originated in work by Professor Frank M. Ng and colleagues in the Department of Biochemistry and Molecular Biology at Monash University, Clayton, Victoria, Australia, asking whether growth hormone’s fat-mobilizing activity could be separated from its growth-promoting and insulin-antagonizing effects. It was developed commercially by Metabolic Pharmaceuticals Ltd (Australia).
Current regulatory status
AOD-9604 is not FDA-approved as a drug for any indication, and its obesity drug program was discontinued in 2007 after the pivotal trial failed. It later received “generally recognized as safe” (GRAS) status as a food ingredient — a separate regulatory category from drug approval, and not a finding of efficacy. AOD-9604 was nominated to FDA’s bulk drug substances list for pharmacy compounding; the nomination was withdrawn.
Analytical testing
HPLC and LC-MS provide complementary purity and identity information. Because the molecule contains a disulfide bridge, correct disulfide formation (not just sequence) is part of establishing identity, and net peptide content is a separate analytical question again.
Ordering from Great Falls
MontanaPep, also known as Montana Peptides, is an independently owned supplier based at 715 13th Ave S, Great Falls, Montana. Local pickup is available by arrangement, and we ship to research addresses across Montana including Billings, Missoula, Bozeman, Helena, Butte, Kalispell and Havre. Call (406) 799-0812 or email customerservice@montanapep.com.